Phase II study of Eribulin every other week maintenance therapy, after induction therapy of Eribulin on day1 and 8 for 3 cycles, in patients with hormone receptor positive and HER2-negative advanced recurrent breast cancer.

Trial Profile

Phase II study of Eribulin every other week maintenance therapy, after induction therapy of Eribulin on day1 and 8 for 3 cycles, in patients with hormone receptor positive and HER2-negative advanced recurrent breast cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2016 Planned End Date changed from 30 Apr 2018 to 31 Oct 2019.
    • 08 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top